Recent Advances in Anti-Obesity Agents / 대한내과학회지
Korean Journal of Medicine
;
: 501-508, 2018.
Article
Dans Coréen
| WPRIM
| ID: wpr-718868
ABSTRACT
Obesity is a chronic disorder that is a significant risk factor for diabetes, cardiovascular diseases, malignancy, and other chronic diseases. Lifestyle modifications form the basis of most treatments for obesity, but it has become clear that such modifications alone are not enough for many obese patients. When a behavioral approach is insufficient, pharmacological treatment may be recommended. In recent years, the US Food and Drug Administration (FDA) has withdrawn several therapeutic options for obesity due to their side effects, but has approved four novel anti-obesity agents. Until recently, orlistat was the only drug approved for the management of long-term obesity, but the US FDA approved the novel anti-obesity drugs lorcaserin and phentermine/topiramate in 2012, and naltrexone/bupropion and liraglutide in 2014. The present review discusses the different pharmacotherapeutic options for the treatment of obesity.
Texte intégral:
Disponible
Indice:
WPRIM (Pacifique occidental)
Sujet Principal:
Food and Drug Administration (USA)
/
Maladies cardiovasculaires
/
Maladie chronique
/
Facteurs de risque
/
Agents antiobésité
/
Liraglutide
/
Mode de vie
/
Obésité
Type d'étude:
Etude d'étiologie
/
Facteurs de risque
Limites du sujet:
Humains
langue:
Coréen
Texte intégral:
Korean Journal of Medicine
Année:
2018
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS